has reported a Net Sales of INR 301.32 Million in Q1FY17 as compared to INR 245.29 Million for the previous corresponding period, thereby registering a growth of 23%. The company's net profit for Q1FY17 is recorded at INR 59.99 Million as against INR 46.63 Million for the previous corresponding period, thereby registering a growth of 29%.
Earnings per Share for the Q1FY17 are at INR 7.05 as against INR 5.48 for Q1FY16. Net Profit margin for Q1FY17 is 19.91% of sales as against 19.01% in Q1 FY 16.
The growth drivers continue to be inventory management, credit controls and product mix.
The installation of a solar power generation project for 100KW has contributed towards reduction in energy costs up to INR 0.30 million in the first quarter.
The sales in the poultry divisions grew by 19% while the Large Animal divisions have shown a growth of 41%.
The company got the manufacturing license for 3 poultry vaccines during the quarter; with this company’s product portfolio has grown to 49 vaccines and 35 health products.
Domestic sales grew by 21% while exports grew by 14%.
Hester Biosciences Ltd is currently trading at Rs. 794.35, up by Rs. 12.7 or 1.62% from its previous closing of Rs. 781.65 on the BSE.
The scrip opened at Rs. 791.7 and has touched a high and low of Rs. 825 and Rs. 788 respectively. So far 33508(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 664.94 crore.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 823.9 on 22-Jun-2016 and a 52 week low of Rs. 337 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs. 803.45 and Rs. 721.9 respectively.
The promoters holding in the company stood at 54.07 % while Institutions and Non-Institutions held 1.51 % and 44.42 % respectively.
The stock is currently trading above its 50 DMA.